Altimmune, Inc. (NASDAQ:ALT) Receives $17.40 Average PT from Analysts

Shares of Altimmune, Inc. (NASDAQ:ALT) have earned an average rating of “Hold” from the eight analysts that are currently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, one has given a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $17.40.

Several equities analysts have issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Altimmune in a report on Monday, October 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Altimmune in a report on Wednesday, October 8th. The Goldman Sachs Group raised shares of Altimmune to a “strong sell” rating in a report on Thursday, July 10th. B. Riley dropped their price objective on shares of Altimmune from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Wednesday, August 13th. Finally, JMP Securities dropped their price objective on shares of Altimmune from $25.00 to $15.00 and set a “market outperform” rating on the stock in a report on Thursday, July 10th.

Altimmune Price Performance

NASDAQ ALT opened at $3.75 on Monday. The firm’s fifty day simple moving average is $3.86 and its two-hundred day simple moving average is $4.54. The company has a current ratio of 20.44, a quick ratio of 20.44 and a debt-to-equity ratio of 0.09. Altimmune has a 12-month low of $2.90 and a 12-month high of $11.16. The firm has a market capitalization of $330.96 million, a P/E ratio of -3.18 and a beta of 0.07.

Altimmune (NASDAQ:ALT) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.05. Altimmune had a negative net margin of 438,730.03% and a negative return on equity of 62.63%. The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.00 million. Analysts forecast that Altimmune will post -1.35 EPS for the current fiscal year.

Institutional Investors Weigh In On Altimmune

A number of large investors have recently made changes to their positions in ALT. Bank of New York Mellon Corp grew its holdings in shares of Altimmune by 1.2% during the first quarter. Bank of New York Mellon Corp now owns 189,000 shares of the company’s stock valued at $945,000 after buying an additional 2,162 shares during the last quarter. Concurrent Investment Advisors LLC purchased a new stake in shares of Altimmune during the first quarter valued at $108,000. Brown Wealth Management LLC grew its holdings in shares of Altimmune by 100.0% during the first quarter. Brown Wealth Management LLC now owns 100,024 shares of the company’s stock valued at $500,000 after buying an additional 50,024 shares during the last quarter. Federated Hermes Inc. purchased a new stake in shares of Altimmune during the first quarter valued at $939,000. Finally, Jefferies Financial Group Inc. purchased a new stake in shares of Altimmune during the first quarter valued at $125,000. 78.05% of the stock is owned by hedge funds and other institutional investors.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.